Original Article 3
The use survey of antihyperuricemic in clinicians
2018 Volume 42 Issue 1 Pages 23-29
Details
2018 Volume 42 Issue 1 Pages 23-29
The 2nd edition of guideline for the management of hyperuricemia and gout was published in 2011 and about 6 years have passed (The 1st edition, in 2002, the 2nd edition is issued in 2010.). During that time, several XOR inhibitors, febuxostat (launched in May, 2011) and topiroxostat (launched in September, 2013) were developed and launched.
We had no new development in Japan for about 40 years since Allopurinol was developed but, these new XOR inhibitor were developed and new choice of medicines was born besides usual uricosuric drugs. From this, we conducted a questionnaire survey for actual status of anti-hyperuricemic drugs for clinicians.
186 valid response have collected from whole 665 questionnaire distribution.
Most physicians have used several drugs appropriately as anti-hyperuricemic with Febuxostat (183 people), Allopurinol (161 people), Benzbromarone (153 people), Topiroxostat (86 people).
As the standard of uric acid level to use anti-hyperuricemic drugs was more than 8 or 9mg/dL (85.5%) in the case without complications, and more than 7 or 9mg/dL (91.4%) in the case with complications.
In addition to that, 85.5% of the whole have almost achieved the goal of uric acid level including "It was achieved by all patients mostly, (100%)" and "It was achieved by almost all patient (75%)".
As a result, it was indicated that the use of antihyperuricemic based on guideline for the management of hyperuricemia and gout was established generally.
